Targeting the FXR Nuclear Receptor to Treat Liver Disease
- 1 April 2015
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 148 (4) , 704-706
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic AcidGastroenterology, 2015
- Nuclear Receptors, RXR, and the Big BangCell, 2014
- Bile acid receptors as targets for drug developmentNature Reviews Gastroenterology & Hepatology, 2013
- Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liverHepatology, 2012
- Hepatic FXR: key regulator of whole-body energy metabolismTrends in Endocrinology & Metabolism, 2011
- Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCAMini-Reviews in Medicinal Chemistry, 2011
- Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1Nucleic Acids Research, 2010
- Genome‐wide tissue‐specific farnesoid X receptor binding in mouse liver and intestine†Hepatology, 2010
- Deciphering the nuclear bile acid receptor FXR paradigmNuclear Receptor Signaling, 2010
- 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic ActivityJournal of Medicinal Chemistry, 2002